Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
CHEMM Stock Overview
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis in Denmark, the United States, Canada, rest of Europe, and internationally.
ChemoMetec Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr.708.50 |
52 Week High | kr.1,149.00 |
52 Week Low | kr.595.50 |
Beta | 1.36 |
1 Month Change | -21.50% |
3 Month Change | -0.28% |
1 Year Change | 12.64% |
3 Year Change | 318.74% |
5 Year Change | 1,884.59% |
Change since IPO | 3,120.46% |
Recent News & Updates
Here's Why I Think ChemoMetec (CPH:CHEMM) Is An Interesting Stock
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Do ChemoMetec's (CPH:CHEMM) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Shareholder Returns
CHEMM | DK Life Sciences | DK Market | |
---|---|---|---|
7D | 1.2% | 1.7% | 1.5% |
1Y | 12.6% | -12.8% | 3.4% |
Return vs Industry: CHEMM exceeded the Danish Life Sciences industry which returned -11.3% over the past year.
Return vs Market: CHEMM exceeded the Danish Market which returned 3.3% over the past year.
Price Volatility
CHEMM volatility | |
---|---|
CHEMM Average Weekly Movement | 7.7% |
Life Sciences Industry Average Movement | 7.8% |
Market Average Movement | 6.6% |
10% most volatile stocks in DK Market | 10.8% |
10% least volatile stocks in DK Market | 4.0% |
Stable Share Price: CHEMM is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: CHEMM's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 143 | Steen Sondergaard | https://chemometec.com |
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis in Denmark, the United States, Canada, rest of Europe, and internationally. The company offers automated cell counters and image analyzers, such as NucleoCounter NC-3000, an advanced image cytometer to characterize cell properties; NucleoCounter NC-250, an automated cell analyzer to characterize cell properties; NucleoCounter NC-202, a consistent cell counter; and NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination. It also provides NucleoCounter YC-100, an automated yeast cell counter used to measure the total cell count and viability of yeast cells in suspension; NucleoCounter SP-100, a sperm cell counter that offers total sperm concentration and sperm viability in a semen sample from ejaculates or extended doses; and NucleoCounter SCC-100, a somatic cell counter used to measure the number of somatic cells in a milk sample.
ChemoMetec Fundamentals Summary
CHEMM fundamental statistics | |
---|---|
Market Cap | kr.12.33b |
Earnings (TTM) | kr.131.26m |
Revenue (TTM) | kr.357.95m |
94.0x
P/E Ratio34.5x
P/S RatioIs CHEMM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CHEMM income statement (TTM) | |
---|---|
Revenue | kr.357.95m |
Cost of Revenue | kr.40.88m |
Gross Profit | kr.317.07m |
Other Expenses | kr.185.81m |
Earnings | kr.131.26m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | 7.54 |
Gross Margin | 88.58% |
Net Profit Margin | 36.67% |
Debt/Equity Ratio | 0.3% |
How did CHEMM perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield53%
Payout RatioValuation
Is ChemoMetec undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
93.97x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CHEMM (DKK708.5) is trading above our estimate of fair value (DKK107.31)
Significantly Below Fair Value: CHEMM is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CHEMM is poor value based on its PE Ratio (94x) compared to the European Life Sciences industry average (45.3x).
PE vs Market: CHEMM is poor value based on its PE Ratio (94x) compared to the Danish market (13.9x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CHEMM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CHEMM is overvalued based on its PB Ratio (43.6x) compared to the XE Life Sciences industry average (3.4x).
Future Growth
How is ChemoMetec forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
15.4%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ChemoMetec has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has ChemoMetec performed over the past 5 years?
Past Performance Score
5/6Past Performance Score 5/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
47.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CHEMM has a high level of non-cash earnings.
Growing Profit Margin: CHEMM's current net profit margins (36.7%) are higher than last year (30.4%).
Past Earnings Growth Analysis
Earnings Trend: CHEMM's earnings have grown significantly by 47.8% per year over the past 5 years.
Accelerating Growth: CHEMM's earnings growth over the past year (77.4%) exceeds its 5-year average (47.8% per year).
Earnings vs Industry: CHEMM earnings growth over the past year (77.4%) exceeded the Life Sciences industry 50.8%.
Return on Equity
High ROE: CHEMM's Return on Equity (46.4%) is considered outstanding.
Financial Health
How is ChemoMetec's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: CHEMM's short term assets (DKK238.6M) exceed its short term liabilities (DKK77.5M).
Long Term Liabilities: CHEMM's short term assets (DKK238.6M) exceed its long term liabilities (DKK11.1M).
Debt to Equity History and Analysis
Debt Level: CHEMM has more cash than its total debt.
Reducing Debt: CHEMM's debt to equity ratio has reduced from 35.3% to 0.3% over the past 5 years.
Debt Coverage: CHEMM's debt is well covered by operating cash flow (16739.8%).
Interest Coverage: CHEMM's interest payments on its debt are well covered by EBIT (259.7x coverage).
Balance Sheet
Dividend
What is ChemoMetec current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
0.56%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CHEMM's dividend (0.56%) isn’t notable compared to the bottom 25% of dividend payers in the Danish market (1.39%).
High Dividend: CHEMM's dividend (0.56%) is low compared to the top 25% of dividend payers in the Danish market (5.91%).
Stability and Growth of Payments
Stable Dividend: CHEMM is not paying a notable dividend for the Danish market, therefore no need to check if payments are stable.
Growing Dividend: CHEMM is not paying a notable dividend for the Danish market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: CHEMM is not paying a notable dividend for the Danish market.
Cash Payout to Shareholders
Cash Flow Coverage: CHEMM is not paying a notable dividend for the Danish market.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.3yrs
Average management tenure
CEO
Steen Sondergaard (62 yo)
2.33yrs
Tenure
Mr. Steen Sondergaard is the Chief Executive Officer at ChemoMetec A/S since January 2020 and served as its Chief Operating Officer & President.
Leadership Team
Experienced Management: CHEMM's management team is considered experienced (2.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
ChemoMetec A/S's employee growth, exchange listings and data sources
Key Information
- Name: ChemoMetec A/S
- Ticker: CHEMM
- Exchange: CPSE
- Founded: 1997
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr.12.335b
- Shares outstanding: 17.41m
- Website: https://chemometec.com
Number of Employees
Location
- ChemoMetec A/S
- Gydevang 43
- Allerød
- Capital Region of Denmark
- 3450
- Denmark
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/18 00:00 |
End of Day Share Price | 2022/05/18 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.